MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

P. Mukherjee, L. B. Pathangey, J. B. Bradley, T. L. Tinder, G. D. Basu, E. T. Akporiaye, S. J. Gendler

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

A MUC1-based vaccine was used in a preclinical model of colon cancer. The trial was conducted in a MUC1-tolerant immune competent host injected with MC38 colon cancer cells expressing MUC1. The vaccine included: MHC class I-restricted MUC1 peptides, MHC class II-restricted pan-helper-peptide, unmethylated CpG oligodeoxynucleotide, and granulocyte macrophage-colony stimulating factor. Immunization was successful in breaking MUC1 self-tolerance, and in eliciting a robust anti-tumor response. The vaccine stimulated IFN-γ-producing CD4+ helper and CD8+ cytotoxic T cells against MUC1 and other undefined MC38 tumor antigens. In the prophylactic setting, immunization caused complete rejection of tumor cells, while in the therapeutic regimen, tumor burden was significantly reduced.

Original languageEnglish (US)
Pages (from-to)1607-1618
Number of pages12
JournalVaccine
Volume25
Issue number9
DOIs
StatePublished - Feb 19 2007

Keywords

  • Colon cancer
  • CpG ODN
  • GM-CSF
  • MUC1

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model'. Together they form a unique fingerprint.

  • Cite this

    Mukherjee, P., Pathangey, L. B., Bradley, J. B., Tinder, T. L., Basu, G. D., Akporiaye, E. T., & Gendler, S. J. (2007). MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine, 25(9), 1607-1618. https://doi.org/10.1016/j.vaccine.2006.11.007